XTX Topco’s Ovid Therapeutics OVID Stock Holding History

XTX Topco’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$252K	Sell	113,393 -75,063	-40%	-$134K	﹤0.01%	2638
2025 Q4	$307K	Buy	188,456 +5,158	+3%	+$7.95K	0.01%	2045
2025 Q3	$238K	Buy	183,298 +104,878	+134%	+$90.9K	0.01%	1700
2025 Q2	$25.9K	Sell	78,420 -14,734	-16%	-$4.44K	﹤0.01%	2129
2025 Q1	$29.1K	Buy	+93,154	New	+$57.3K	﹤0.01%	2088
2024 Q4	–	Sell	-38,230	Closed	-$45.1K	–	2763
2024 Q3	$45.1K	Buy	38,230 +12,076	+46%	+$12.6K	﹤0.01%	1709
2024 Q2	$20.1K	Buy	+26,154	New	+$72.8K	﹤0.01%	1612
2021 Q3	–	Sell	-50,569	Closed	-$198K	–	964
2021 Q2	$198K	Buy	+50,569	New	+$200K	0.07%	567

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

XTX Topco's OVID Position: Q1 2026 in Review

XTX Topco reduced its Ovid Therapeutics (OVID) stake by 40% in Q1 2026, selling an estimated $134K and leaving 113,393 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

XTX Topco first reported a position in OVID in Q2 2021 and has held it in 8 quarters since. The position peaked at $307K in Q4 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

XTX Topco held 113,393 shares of Ovid Therapeutics worth $252K as of Q1 2026.
XTX Topco sold 75,063 Ovid Therapeutics shares in Q1 2026, an estimated $134K.
Ovid Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2638 holding.
XTX Topco first reported a position in Ovid Therapeutics in Q2 2021 and has held it in 8 quarters since.
XTX Topco's Ovid Therapeutics position peaked at $307K in Q4 2025.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.